**Abstract**

**Aims:** Long-acting injectable antipsychotics (LAIs) are an important therapeutic option for patients with schizophrenia. Despite good clinical evidence, namely the reduction of relapse rates and duration of hospitalization, some clinicians believe that LAIs are unacceptable to patients due to injection site pain or constriction of the patients' autonomy. The objective of this study was to assess the attitudes toward LAIs among patients with schizophrenia in Japan.

**Method:** Using a cross-sectional design, we recruited patients with a DSM-IV diagnosis of schizophrenia who were admitted to three psychiatric hospitals from February to July 2014. The demographic data (age, sex, duration of education) and medical history of the subjects were obtained from their medical records. The Clinical Global Impressions-Severity of Illness (CGI-S) Scale and the Global Assessment of Functioning (GAF) were used to measure symptom severity and evaluate a patient's general functions. We employed an original questionnaire specifically to survey patients' andpsychiatrists' attitudes toward LAIs. This study was approved by the Ethics Committee of the Hirosaki University School of Medicine, and all subjects provided written informed consent before participating in this study.

**Results:** As a recognition of LAIs, psychiatrists thought that 39.0 (60/154) % of patients are "very suitable" or "suitable" for treatment with LAIs. On the other hand, only 9.7 (15/158) % of patients thought that LAIs is "very suitable" or "suitable" for them. More than half of patients thought that LAIs are fewer side effects and more reliable therapeutic option.

**Conclusions:** Our results clarified the gaps of attitudes toward LAIs between psychiatrists and patients with schizophrenia. Positive impression concerning side effects may promote uptake of newer LAIs.
